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Background: Renal cell carcinoma (RCC) is marked by high mortality rate. To date, no robust risk stratification by
clinical or molecular prognosticators of cancer-specific survival (CSS) has been established for early stages. Transcriptional
profiling of small non-coding RNA gene products (miRNAs) seems promising for prognostic stratification. The expression
of miR-21 and miR-126 was analysed in a large cohort of RCC patients; a combined risk score (CRS)-model was
constructed based on expression levels of both miRNAs.
Methods: Expression of miR-21 and miR-126 was evaluated by qRT-PCR in tumour and adjacent non-neoplastic
tissue in n = 139 clear cell RCC patients. Relation of miR-21 and miR-126 expression with various clinical parameters
was assessed. Parameters were analysed by uni- and multivariate COX regression. A factor derived from the z-score
resulting from the COX model was determined for both miRs separately and a combined risk score (CRS) was
calculated multiplying the relative expression of miR-21 and miR-126 by this factor. The best fitting COX model
was selected by relative goodness-of-fit with the Akaike information criterion (AIC).
Results: RCC with and without miR-21 up- and miR-126 downregulation differed significantly in synchronous
metastatic status and CSS. Upregulation of miR-21 and downregulation of miR-126 were independently prognostic.
A combined risk score (CRS) based on the expression of both miRs showed high sensitivity and specificity in predicting
CSS and prediction was independent from any other clinico-pathological parameter. Association of CRS with CSS was
successfully validated in a testing cohort containing patients with high and low risk for progressive disease.
Conclusions: A combined expression level of miR-21 and miR-126 accurately predicted CSS in two independent RCC
cohorts and seems feasible for clinical application in assessing prognosis.
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Tumour markersBackground
The incidence of RCC is increasing annually by about
2% [1]. Over 200 000 new cases are diagnosed per year
and more than 100 000 related deaths occur globally [2].
RCC is marked by adverse tumour biology and its CSS
ranks lowest among urological malignancies [3]. RCC is
clinically demanding due to its prognostic heterogeneity.
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reproduction in any medium, provided the orbeen hindered by lacking reliability of prediction of
outcome by both clinical and molecular parameters.
Therefore, identification of novel markers is warranted
for tailoring therapy and follow-up. One current ap-
proach for molecular tumour characterization is profil-
ing of microRNA (miR) expression [4]. MiRs are small
noncoding RNA strands posttranscriptionally regulat-
ing gene expression and appearing to be modulators of
urologic cancers [5]. Among the large number of miRs,
miR-21 and miR-126 have received special attention
because of their relationship with multiple cancer en-
tities. Upregulation of miR-21 has been reported e.g. inLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1471-2407/14/25breast, gastric and lung cancer [4]. A respective role
has also been suggested for urological malignancies. In
prostate cancer, elevated expression of miR-21 alone
was shown to convey castration resistance [6]. In RCC,
several studies describe upregulation of miR-21 [7,8]
and recently, association with reduced survival [9], in-
dicating a pathogenetical role of miR-21 as a so-called
oncomiR.
Such role has also been suggested for miRNA-126,
which is mapped within its host gene EGFL-7 (epidermal
growth factor like-7) and is highly expressed in vascular
endothelial cells [10]. By regulating the VEGF (vascular
endothelial growth factor) pathway miR-126 plays an im-
portant role in angiogenesis, lymphangiogenesis and ves-
sel integrity in endothelial cells as well as in cancer cells
[11]. In several studies miR-126 was reported to act as a
tumour suppressor and was shown to be downregulated
in various cancer types including breast, gastric, prostate
cancer and RCC [11,12]. In non-small cell lung and oral
squamous cell cancer downregulation of miR-126 was
related to poor survival suggesting miR-126 to be prog-
nostic [13,14]. In metastatic colorectal cancer miR-126
was related to the response of treatment with capecita-
bine and oxaliplatin [15]. In RCC miR-126 is described
to play a role in molecular classification of different sub-
types [12] and recently, association of downregulation
with progression was supposed [16,17].
While dysregulation of miR-21 and miR-126 has been
linked to metastasis and progression in many cancer
types, to date data on RCC are scarce. To assess a poten-
tial role of these miRs as prognostic molecular markers
in RCC we analysed the expression of both miRs in 139
clear cell RCC specimens aiming at clinical application
as molecular markers.
Methods
Patients and tissue sample preparation
Fresh frozen samples of clear-cell RCC and adjacent his-
tologically benign renal tissue of patients undergoing
radical nephrectomy or nephron-sparing surgery at the
Department of Urology and Paediatric Urology of the
Julius- Maximilians-University Medical Centre Würzburg
between 2006–2010 were included in the study. Fresh
specimens were collected, snap frozen in liquid nitro-
gen immediately after resection, and directly stored
at -80C until RNA extraction was performed. Samples
from cancerous areas were isolated from non-necrotic
parts of the tumour tissue. Tumour classification and
staging were performed according to the 2004 World
Health classification and the 2002 TNM System. The
study was approved by the Ethical Review Board of
the Julius-Maximilian-University Würzburg (no. 136/08)
and written informed consent was obtained from all
patients.RNA extraction and quantitative real time PCR
Total RNA from frozen tissue was isolated using the
miRNAeasy kit (Quiagen, Hilden, Germany) according to
the manufacturer’s instructions. RNA concentration and
A260/280 ratio were analysed with a Nano Drop ND-100
spectrometer (NanoDrop Technologies, Wilmington) and
RIN (RNA Integrity Numbers) and calculated with a Bioa-
nalyzer. RNA samples showing RIN < 6.0 were excluded
from further analysis. The resulting miRNA was retained
for quantitative Real Time PCR (qRT-PCR).
QRT-PCR was performed using TaqMan Micro
Array assays (Applied Biosystems) as described previ-
ously. 5 ng total RNA was used for microRNA-specific
reverse transcription as recommended by the manufac-
turer for miR-21 and miR-126. Cycling conditions were
chosen according to manufacturer’s protocols. All re-
actions were performed in triplicates and samples
showing SD > 0.5 were excluded. Relative expression
values of miRs were normalized to small nuclear RNA
(RNU6b) previously described as reference gene [18].
ΔCt for tumour samples and adjacent non neoplastic
tissue of the two miRs were performed by the com-
parative Ct method. Relative over- or underexpression
of miRs in tumours compared to the normal adjacent
kidney tissue was obtained by the ΔΔCt method
assuming equal RNA concentrations and complete
efficiency of qRT-PCR as described previously [18]. All
samples characterized by expression levels of RNU6B > 30
Ct were excluded from further analysis (Additional file 1:
Table S1).
Statistics, computational analysis and combined risk score
calculation
Thresholds for dichotomising relative expressions of
miR-21 and miR-126 were determined by receiver oper-
ating characteristic (ROC) curve, based on CSS. Impact
of clinic-pathological parameters, miR-21 and miR-126
on CSS was assessed by uni- and multivariate COX re-
gression analysis (R package, Thernaux, 2000). Calcula-
tion of a CRS of miR-21 and miR-126 was implemented
as proposed by Lossos et al. [19]. Therefore, a factor de-
rived from the z-score, resulting from the COX model,
was determined for both miRs separately and the relative
expression multiplied by this factor resulting in the
formula (−2.1 × miR-126) + (2.6 × miR-21). The negative
factor indicates that higher expression correlates with
longer survival, whereas the positive factor correlates
with shorter survival. A cut-off for the risk score was
again determined by ROC curve. The best fitting COX
model was selected by measuring the relative good
ness-of-fit with the Akaike information criterion (AIC).
Differences in mean between miR- expression and clin-
ical parameters were analysed by Student’s t-test and
ANOVA.
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Expression of miR-21 and miR-126 in RCC
As previously described by other studies miR-21 and miR-
126 was expressed in normal kidney tissue and in RCC
samples (Additional file 1: Table S1). Moreover, we found
a significant upregulation of miR-21 in RCC (Figure 1A)
compared to adjacent renal tissue by qRT-PCR. Clinical
and pathological characteristics of the used collective are
summarized in Table 1. The ΔΔCt method demonstrated
miR-21 to be upregulated more than two-fold in 65% of
the RCC cases. In addition to the known oncomiR miR-21
we analysed expression of miR-126 in our study collective.
As shown in Figure 1A no significantly different overall
expression of miR-126 between malign and benign
samples was observed. However, the standard deviation
(SD) of miR-126 expression in RCC samples showed2
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Figure 1 Expression of miR-126 and miR-21 in RCC. Box-Whisker-Plot :
tissue (n = 103). MiR-21 expression is significantly higher in RCC (p < 0,001
compared to the expression of control tissue. Expression was analysed by
unpaired students t-test. B) Proportion of RCC patients with dysregulation
tissue was verified by qRT-PCR in triplicates. MiR expression ratio of each tumo
normal tissue was calculated by the ΔΔCt method. All patients were divided i
miR-126 in RCC.greater variation compared to the SD in histologically
benign tissue (Figure 1A). The comparative ΔΔCt
method showed a more than twofold downregulation
and a more than two-fold upregulation of miR-126 in
36 (35%) and 22 (22%) RCC samples, respectively
(Figure 1B). From these results we concluded that
miR-126 was silenced or upregulated in different sub-
groups of the RCC study cohort resulting in comparable
mean expression between RCC cases and adjacent normal
renal tissue.
Association of miR-21 and miR-126 expression with
clinical parameters in RCC
To test a potential clinical relevance of miR-21 or miR-
126, we analysed their expression in different risk groups
stratified by conventional clinical parameters. Expression0
0
0
0
0
0
<2 x-down normal >2x- up
miR-21
<2 x-down normal >2x- up
miR-126
A) Relative expression of miR-21 and miR-126 in RCC and normal renal
), but overall miR-126 expression is not changed (p = 0.57) in RCC
qRT-PCR and normalized against RNU6b. P-values were calculated by
of miR-21 and miR-126: Expression of miRs in tumour and control
ur specimen compared to the expression in corresponding adjacent
nto three groups by > < 2 fold up- or down-regulation of miR-21 or
Table 1 Clinical and pathological patient characteristics
(n = 103)
Clinical/ patholigical features n
Age, years (range) 65 (32–91)
Follow up, months (st. dev) 33 (± 15, 2)
Pathological tumor stage
pT1a 27, (26, 2%)
pT1b 28 (27, 2%)
pT2 11 (10, 7%)
pT3a 7 (6, 8%)
pT3b 28 (27, 2%)
pT3c 2 (1, 9%)
Grading
1 12 (11, 7%)
2 69 (66, 9%)
3 22 (21, 4%)
Metastasis at time of surgery
No 88 (84, 5%)
Yes 16 (15, 5%)
Surgery
nephron sparing 26 (25, 2%)
pT1a 67% (18 of 27 patients)
pT1b 29% (8 of 28 patients)
pT2-3c 0% (0 of 48 patients)
nephrectomy 77 (74, 8%)
Clinical failure
No 82 (79, 6%)
Yes 21 (20, 4%)
Cancer related death
No 87 (84, 5%)
Yes 16 (15, 5%)
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http://www.biomedcentral.com/1471-2407/14/25of miR-21 tended to be reduced in lower compared to
higher tumour stages and grades. Conversely, miR-126
tended to be higher in lower compared to higher tumour
stages and grades. Both trends missed the level of statis-
tical significance (Figure 2A and B).
Of 103 RCC patients in the present series, 16 showed
synchronous metastasis (Table 1). In cases with syn-
chronous metastasis versus those without, significant
upregulation of miR-21 (p=0,02) and a trend towards
downregulation of miR-126 missing the level of statis-
tical significance was found (p = 0.08) (Figure 2C). But
three patients with synchronous metastasis showed low
miR-21 expression and notably two of these three cases
had CSS exceeding three years. We concluded from
these results that dysregulation of both miRs might be
involved in metastasis and progression of RCC.Association of miR-21 and miR-126 expression with over-
all survival in RCC
We found upregulation of miR-21 and downregulation of
miR-126 to be associated with CSS, respectively (Figure 2D).
The study group was dichotomized by a ROC curve and
sensitivity and specificity were calculated (Figure 3A). A
threshold ΔΔCt = 1.61 for miR-21 and ΔΔCt = 0.57 for
miR-126 provided a sensitivity and specificity of 66% and
81% and of 36% and 100%, respectively (Figure 4A and B).
In Kaplan-Meier analysis upregulation of miR-21 and
downregulation of miR-126 were related to adverse out-
come (log rank p < 0.001 for miR-21 and p < 0.01 for
miR-126, Figure 3B). Expression of both miRs was com-
bined to assess potential improvement of prediction,
sensitivity and specificity. Using a previously described
PCR-based risk score model CRS for CSS was calculated
[19]. A cut-off of the CRS of 6.82 stratified 36 (35%)
cases in the high and 67 (65%) in the low risk group,
respectively.
Out of 16 cases with cancer-related death (CRD) dur-
ing follow-up 14 were grouped in the predicted high
risk and 65 out of 87 cases without CRD throughout
follow-up in the low risk group, respectively. As shown
in Figure 4 and Table 2 the CRS correctively classified
75% low risk cases and 88% high risk cases. Compared
to singular miRNAs, sensitivity (88%) and specificity
(75%) were increased by CRS (Figure 4A and B).
Kaplan-Meier estimates showed that CRS correlated
significantly with CSS (log rank p < 0.0001); predicted 5
year CSS rates were 96% for low and 48% for high risk
patients, respectively.
Prognostic model combining miR-21 and miR-126
expression
The potential of the two dichotomised miRNAs and the
combined risk score (CRS) to predict overall survival in
comparison to clinicopathological factors like tumour
stage or grade was evaluated by uni- and multivariate Cox
regression analysis. In Univariate Cox regression analysis
CRS (Table 3) and both single miRs (Additional file 2:
Table S2) were significantly prognostic for CSS (p < 0.0001
for CRS, p < 0.0002 for miR-126 and p < 0.0008 for miR-
21; the estimate of a coefficient for miR-126 was infinity
since there were no events in one group) as well as
tumour stage and grade, and in contrast to age and gender,
which were not significant. By stepwise regression analysis
the best model for predicting CSS (tested by AIC) con-
tained the CRS (HR: 19,37; p < 0,0002) and the clinico-
pathological factor tumour grade (HR: 13.88; p < 0.001)
indicating that both of these factors were independent pre-
dictors of CSS in the study cohort. To internally validate
this result we performed bootstrap analysis of our re-
gression model. The bootstrap estimates generated
comparable hazard ratios and confidence intervals for
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Figure 2 MiR-21 and miR-126 expression in association to clinical parameters. Box-Whisker-Plot: relative expression of miR-21 and miR −126
was analysed by the ΔΔCt method in RCC cases and subsequently the cases were divided into subgroups based on tumor grade (A), T stage
(B) the presence of synchrone metastasis (C) or cancer related death (CRD) (D). P-values were calculated by students paired t-test (C and D) or by
ANOVA (A and B).
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http://www.biomedcentral.com/1471-2407/14/25both factors, suggesting a robust regression model and
excellent internal validation (Table 3). To evaluate the
ability of miR-21 and miR-126 to predict survival we
calculated a regression model by substituting the CRS
with the separate dichotomised miR-21 and miR-126 ex-
pression data (Additional file 2: Table S2). Again, tumor
grade and both miRs were shown to be independent
factors in the regression model. Comparison of both
regression models indicated that the combined risk
score was a better predictor than the individual miRs.
Validation of the combined risk score (CRS) as prognostic
factor in RCC
To validate the predictive potential of the model the de-
termined high risk cut-off level of CRS (CRS > 6.82) was
used to classify a test cohort for prognostic risk stratifi-
cation. The test dataset contained 16 high risk patients
with early disease progression and cancer-specific death(<48 months) and 20 low risk patients characterized by
progression-free survival for over 48 months and no
cancer-specific death in the follow-up time. We deter-
mined miR-21 and miR-126 expression and subsequently
the CRS in samples of the validation cohort and calcu-
lated the predictive power of the CRS. Among the high
risk group 13 of 15 (86.7%) and among the low risk
group 17 of 20 (85%) cases were classified correctly by
CRS (Figure 4C and D, Table 2). Samples of the valid-
ation cohort with CRS over the previously determined
cut-off level were found to be associated with CRD by
univariant Cox regression analysis (HR (95% CI) =1.39
(1.18-1.62); p < 0,0001).
Discussion
Clinical management of RCC has changed in recent
years with increased incidental diagnosis and by initiat-
ing therapy in localized stages and the establishment of
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Figure 3 ROC curve of miRNA risk scores (miR-21, miR-126 and CRS) and Kaplan Meier survival analysis of cancer specific survival (CSS)
in RCC patients stratified by miR-21, miR-126 and CRS expression data. A) ROC curves; the cross indicates the selected cutoff score for miR-21,
miR126 or CRS resulting in highest sensitivity and specificity. The used cut-off scores were indicated in the graphs. B) Kaplan Meier curves with log rank
test and numbers of patients stratified by the calculated risk scores of miR-21, miR-126 and CRS.
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http://www.biomedcentral.com/1471-2407/14/25antiangiogenic agents. While tumour size at time of
diagnosis has decreased, mortality rate for RCC has not,
suggesting an impact of differential tumour biology in
morphologically similar tumours [20]. Therefore, identi-
fication of patients at high risk for cancer progression is
warranted to tailor adjuvant treatment.
While numerous articles have recently studied asso-
ciations between miRs and carcinogenesis and tumour
progression proposing several so-called oncomiRs as
regulators in carcinogenetic pathways and biomarkers in
many cancer entities, considerably fewer data are avail-
able on such roles of specific miRs in RCC. Whereas
recent expression studies in metastatic or progressive
RCC revealed a large number of different miRs poten-
tially linked to progression [16,21-24], surprisingly only
a small number of miRs have been found to be concor-
dantly differentially expressed in metastasised or pro-
gressive RCC. The small overlap between the different
studies and largely contradictory results remains to beexplained. Therefore, we selected the oncomiRs, miR-21
and miR-126, based on literature search and own un-
published expression analyses as promising markers for
CSS in RCC. As expected, we identified differential
expression of miR-21 in our RCC study cohort, but,
surprisingly, we could not find changes in the overall
miR-126 expression in our study cohort. However,
miR-126 was highly up or down-regulated in sub-
groups of the study collective, balancing the expression
changes of miR-126 in the total RCC collective. Never-
theless, the dysregulation of miR-126 in subgroups of
the RCC collective might indicate a role of miR-126
dysregulation in the development of RCC. This sug-
gestion is supported by previous studies describing an
impact of miR-126 in molecular classification of differ-
ent RCC subtypes [12,16,17].
Among oncogenetic miRNAs, miR-21 may be one of
the most attractive for clinical use. MiR-21 is upregu-
lated in various human cancers [4,6,25]. In vitro data
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Figure 4 Risk stratification of patients with or without cancer related death (CRD). Proportion of patients without (A and C) or with (B and D)
cancer related death stratified by the risk score of miR-21 (high risk: miR-21 expression > 1.61), miR-126 (high risk miR-126 expression <0.57) or CRS
(combined high risk score > 6.82). The proportion of correctly or incorrectly classified patients of the learning cohort (A and B) and the
test cohort (C and D) are shown. The proportion of correctly classified patients at low risk (A and B) is shown as grey bars and indicates
the sensitivity of the different risk scores. B and D show the proportion of correctly classified patients at high risk as black bars and indicate the
specificity of the different risk scores. For both cohorts the CRS shows higher true positive rate and lower false positive rate as the separated miR-21
and miR-126 risk scores.
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http://www.biomedcentral.com/1471-2407/14/25support such notion; cell lines with miR-21 overexpres-
sion increase cell proliferation, migration and invasion
[26]. Zhang et al. showed that knockdown of miR-21
inhibited cell proliferation and induced cell apoptosis by
targeting multiple genes in RCC cells [27]. Association
of miR-21 expression with adverse outcome was re-
ported for various cancer entities, such as breast and
gastric cancer [4]. Such results recently also have been
reported by two previous studies using smaller RCC
study cohorts [7,9]. Our present results stemming from
a considerably larger and unselected series representative
of tertiary cancer care are in line with these data demon-
strating marked upregulation of miR-21 in RCC and sig-
nificant association with synchronous metastasis and
CSS. Our results show miR-21 to be an independent
predictor. In one of the two previous and smaller studies
in RCC Faragalla et al. found miR-21 upregulation to beassociated with CSS, although it was not independent of
tumour stage and grade. While Faragalla used relative
miR-21 expression levels, in the present study levels of
the RCC samples were normalized to adjacent benign
tissue. Thus, the present study is the first to date that
identifies miR-21 as an independent marker for CSS in a
large and representative series using such normalization
mode.
Recently miR-126 has been reported to be a tumour
suppressor in various cancer types including RCC [16,17]
regulating target genes like CRK, VEGF and EGFL7 in
cancer cells [11]. Lately, regulation of pro-angiogenic
genes has been demonstrated in metastatic breast cancer
[28]. Inhibition of apoptosis in leukaemia and promotion
of cancer development in NSCLC or prostate cancer have
also been reported [11,29]. In several miR expression stud-
ies downregulation of miR-126 was associated with
Table 2 Specificity and sensitivity for the CRS in the
learning (A) and test data set (B)
A
Learning data set CRS > 6.8 (n) CRS ≤ 6.8 (n) % correct classified
CRD (n = 16) 14 2 87,50
no CRD (n = 87) 22 65 74,71
overall 76,70
B
Test data set CRS > 6.8 (n) CRS ≤ 6.8 (n) % correct classified
CRD (n = 15) 13 2 86,67
no CRD (n = 20) 3 17 85,00
overall 85,71
CRD: cancer related death; CRS: combined risk score for miR-21 and miR-126.
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http://www.biomedcentral.com/1471-2407/14/25metastatic disease and early relapse after nephrectomy in
smaller series of RCC [16,17]. The present series is the
largest assessing miR-126 as prognostic factor in RCC to
date and the first analysing expression levels normalized
with benign tissue. Finding no overall downregulation of
miR-126 expression we conclude no pivotal role in the ini-
tiation of RCC. Downregulation was significantly related
to synchronous metastasis and independently predicted
CSS. The predominant downregulation of miR-126 in
progressive RCC suggest miR-126 to act as a tumour
suppressor, which is supported by the recent description
of miR-126 regulating VEGF-A in RCC [16], one of the
pivotal factors of angiogenesis and tumour progression.
Currently, no clinically applicable molecular marker of
CSS is available in RCC. To develop an accurate predic-
tion system, we generated a dual-factorial marker model
based on a CRS using the expression levels of miR-21
and miR-126. The determined CRS provided higher sen-
sitivity and specificity compared to risk stratification,
which was based on expression of each single miR. The
CRS is associated with disease prognosis and predicts
CSS independently from other clinicopathological fac-
tors in the analysed RCC cohort. Validation in an inde-
pendent study cohort has shown that the CRS is able to
classify robustly RCC samples into relevant risk groupsTable 3 Univariate and multivariate Cox regression analysis d
(p < 0.00001; Wald-Test) including the combined risk score (C
CSS Univariate
n HR (95% CI) p value
CRS 103 1.107 (1.06-1.12) 2.608e-05
Grading 103 10.97 (3.90-30.9) 5.847e-06
Age 103 0.99 (0.95-1.03) 0.71
pT 103 1.76 (1.25-2.47) 0.001
Gender 103 1.61 (0.55-4.67) 0.38
Wald testwith high sensitivity and specificity suggesting that it
might have potential as a prognostic molecular assay in
a clinical setting. However, the current validation is lim-
ited by various factors, like size of the validation cohort
or applicability of qRT-PCR based expression analysis in
clinical routine. To further test the effectiveness of this
molecular marker model, we are planning to evaluate it
on expanded validation cohorts in the future. Recently, a
miR signature based on the expression of miR-10b, miR-
139, miR-130b and miR-199b was found to be associated
with synchronous metastasis and CSS in RCC [30] pro-
viding similar sensitivity (76%) and specificity (100%) as
our study. Although no direct comparison can be made
and the present series is considerably larger and assessed
two miRs, the 5-year CSS rates predicted by both miR
signatures of 32% and 84% for the high and low risk
cases in the 4-miR signature compared with 48% and
96% in the current study support the robustness of such
models and the impact of certain miRs on RCC. Several
studies have evaluated the prognostic value of clinico-
pathological features like performance status, metastatic
status, lymph node involvement, sarcomatoid features,
perinephritic fat invasion, Fuhrman grade and histo-
logical subtype in RCC patients [31]. We have found
that only tumour grade independently predicts survival
in our study cohort. Tumour stage, sex or age of the pa-
tients did not significantly correlate with prognosis and
survival in our regression model. This might depend on
the limited sample size and follow-up time of our RCC
collective and has to be further validated in larger
cohorts.
Also certain additional limitations of the present ana-
lysis need to be taken into account. For one, only clear-
cell RCC was assessed limiting our conclusions to this
entity. Since it represents the largest and clinically most
relevant subtype, however, the clinical significance of
our data is not diminished and inclusion of clear-cell
RCC only added to the homogeneity of the data. Sec-
ondly, while the present series is among the largest
reported to date and mode of diagnosis, surgical treat-
ment and pathological processing are homogeneous, theetermined by relative goodness of fit with AIC
RS) as variable
Multivariate (AIC) Bootstrap
HR (95% CI) p value HR (95% CI)
19.37 (4.06-92.44) 0,0002 3.97 (3.0-11.83)
13.88 (4.28-45.08) 1,20e-05 3.36 (2.5-11.42)
p = 7.17e-07
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http://www.biomedcentral.com/1471-2407/14/25data acquisition was retrospective and the exact use and
regimens of anti-angiogenic medication and its impact
on CSS could not be assessed. The overall use of antiangio-
genic medication was homogeneously distributed over
the study group and among cases with differential miR
expression limiting respective bias. A further limitation is
the lack of functional data; such was not the focus of the
present study however, since we aimed at establishing
clinical evaluation of miR as prognostic tools rather
than adding basic knowledge on the role of miR in RCC
tumorbiology.
Conclusion
We found a significant correlation of miR-21-upregulation
and miR-126-downregulation with metastasis and CSS in
clear cell RCC. While tumour grade was the only clinico-
pathological parameter independently predicting CSS in
the used study cohort in multivariate analysis, miR-21,
miR-126 and a signature combining expression of both
miRs (CRS), were independent prognosticators and might
add to the limited assessment of prognosis based on clini-
copathological parameters only. The determined CRS was
validated in an independent test cohort showing high sen-
sitivity and specificity in predicting CRD. The presently
described miR signature appears apt to predict CSS in
RCC justifying validation in larger cohorts and subsequent
implication in clinical management.
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